Director – Clinical Development Research Scientist
Avalyn Pharma
Director – Clinical Development Research Scientist
Avalyn Pharma
Inhaled therapies for rare respiratory diseases
About Avalyn:
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.
Position Summary:
The Director, Clinical Development Research Scientist will report to the Senior Vice President, Clinical Development and serve as a key clinical and scientific leader advancing Avalyn’s IPF/ILD clinical development programs. This individual will provide therapeutic-area expertise and strategic leadership across the development lifecycle, from program and study strategy through protocol design, clinical execution, data interpretation, regulatory interactions, and development planning.
The Director will lead one or more clinical trials and partner closely with Clinical Operations, Biostatistics, Regulatory Affairs, Pharmacovigilance, Translational Science, Data Management, CMC, and other functions to ensure clinical trial activities are scientifically rigorous, patient-focused, operationally feasible, and aligned with broader program objectives.
This individual will help shape development strategy, including study design, endpoints, development sequencing, risk assessment, data interpretation, and program-level decision-making. The Director will also provide medical and scientific expertise across multiple studies, serve as a resource to investigators and external experts, and contribute to regulatory interactions, advisory boards, publications, and scientific presentations.
The successful candidate will bring a balance of strategic thinking and hands-on clinical development expertise, with the ability to translate emerging clinical data into actionable development decisions.
Responsibilities:
Clinical Development Strategy & Program Leadership
Study Design & Clinical Trial Leadership
Medical Oversight, Safety & Data Interpretation
Clinical Documentation & Regulatory
Cross-Functional & External Leadership
Scientific Communications
Qualifications:
Proposed pay range 220000 - 242000 USD
Inhaled therapies for rare respiratory diseases
Avalyn Pharma develops inhaled therapies for rare respiratory diseases. Its lead program, AP01, is an inhaled formulation of pirfenidone in Phase 2b trials designed to treat pulmonary fibrosis and other interstitial lung diseases. The inhaled approach aims to deliver therapy directly to the lungs, potentially improving efficacy and convenience while reducing systemic exposure. The company differentiates itself by focusing on inhaled versions of already approved medications to target lung diseases more precisely, addressing conditions with limited treatment options. Its goal is to advance clinical development and move toward commercialization of these inhaled therapies, ultimately improving patient outcomes and quality of life for people with rare lung diseases.
Explore more opportunities at Avalyn Pharma